WO2022010337A3 - Método para reducir la incidencia y prevalencia del virus del papiloma humano (vph) y para proporcionar protección contra infecciones de transmisión sexual - Google Patents

Método para reducir la incidencia y prevalencia del virus del papiloma humano (vph) y para proporcionar protección contra infecciones de transmisión sexual Download PDF

Info

Publication number
WO2022010337A3
WO2022010337A3 PCT/MX2021/000022 MX2021000022W WO2022010337A3 WO 2022010337 A3 WO2022010337 A3 WO 2022010337A3 MX 2021000022 W MX2021000022 W MX 2021000022W WO 2022010337 A3 WO2022010337 A3 WO 2022010337A3
Authority
WO
WIPO (PCT)
Prior art keywords
incidence
human papillomavirus
sexually transmitted
hpv
prevalence
Prior art date
Application number
PCT/MX2021/000022
Other languages
English (en)
French (fr)
Other versions
WO2022010337A2 (es
Inventor
Eleonora SANDERS ESPARZA
Bárbara SANDERS ESPARZA
Original Assignee
Sanders Esparza Eleonora
Sanders Esparza Barbara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/921,360 external-priority patent/US11857675B2/en
Priority claimed from MX2020008778A external-priority patent/MX2020008778A/es
Application filed by Sanders Esparza Eleonora, Sanders Esparza Barbara filed Critical Sanders Esparza Eleonora
Priority to EP21838896.5A priority Critical patent/EP4176886A2/en
Publication of WO2022010337A2 publication Critical patent/WO2022010337A2/es
Publication of WO2022010337A3 publication Critical patent/WO2022010337A3/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08Oxides; Hydroxides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

Métodos que comprenden la inserción de un dispositivo cervical uterino en la parte inferior de la cavidad uterina y endocérvix para disminuir la incidencia del virus del papiloma humano en mujeres, principalmente los tipos 16 y 18, impidiendo de este modo el desarrollo de cáncer cervical uterino; para modificar la microbiota cervical; para incrementar los leucocitos y proteger contra las infecciones de transmisión sexual en las mujeres.
PCT/MX2021/000022 2020-07-06 2021-07-05 Método para reducir la incidencia y prevalencia del virus del papiloma humano (vph) y para proporcionar protección contra infecciones de transmisión sexual WO2022010337A2 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21838896.5A EP4176886A2 (en) 2020-07-06 2021-07-05 Method for reducing the incidence and prevalence of human papillomavirus (hpv) and for providing protection against sexually transmitted infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16/921,360 US11857675B2 (en) 2014-08-06 2020-07-06 Method for reducing the incidence and prevalence of human papilloma virus (HPV) and for providing protection against sexually transmitted infections
US16/921,360 2020-07-06
MX2020008778A MX2020008778A (es) 2020-07-06 2020-08-21 Metodo para reducir la incidencia y prevalencia del virus del papiloma humano (vph) y para proporcionar proteccion contra infecciones de transmision sexual.
MXMX/A/2020/008778 2020-08-21

Publications (2)

Publication Number Publication Date
WO2022010337A2 WO2022010337A2 (es) 2022-01-13
WO2022010337A3 true WO2022010337A3 (es) 2022-04-28

Family

ID=79553536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2021/000022 WO2022010337A2 (es) 2020-07-06 2021-07-05 Método para reducir la incidencia y prevalencia del virus del papiloma humano (vph) y para proporcionar protección contra infecciones de transmisión sexual

Country Status (2)

Country Link
EP (1) EP4176886A2 (es)
WO (1) WO2022010337A2 (es)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0152193A1 (en) * 1984-01-23 1985-08-21 Ortho Pharmaceutical (Canada) Ltd Streamlined t-shaped intrauterine device and method of preventing conception
US20080216842A1 (en) * 2008-02-19 2008-09-11 Guillermo Sanders Acedo Contraceptive device designed for mexican women according to the dimensions of their uterine cavity acoording to their parity
WO2016022016A2 (es) * 2014-08-06 2016-02-11 Guillermo Sanders Acedo Dispositivo cervico uterino que incrementa la protección del riesgo de contraer cáncer cervico uterino
WO2016193987A1 (en) * 2015-05-30 2016-12-08 Pregna International Limited Intrauterine device with a restricted upward movement of a string

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1030795C2 (nl) 2005-12-27 2007-06-28 Willem Arthur Adriaan Van Os Intra-uterine inrichting en huls voor het inbrengen daarvan in de uterus.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0152193A1 (en) * 1984-01-23 1985-08-21 Ortho Pharmaceutical (Canada) Ltd Streamlined t-shaped intrauterine device and method of preventing conception
US20080216842A1 (en) * 2008-02-19 2008-09-11 Guillermo Sanders Acedo Contraceptive device designed for mexican women according to the dimensions of their uterine cavity acoording to their parity
WO2016022016A2 (es) * 2014-08-06 2016-02-11 Guillermo Sanders Acedo Dispositivo cervico uterino que incrementa la protección del riesgo de contraer cáncer cervico uterino
WO2016193987A1 (en) * 2015-05-30 2016-12-08 Pregna International Limited Intrauterine device with a restricted upward movement of a string

Also Published As

Publication number Publication date
EP4176886A2 (en) 2023-05-10
WO2022010337A2 (es) 2022-01-13

Similar Documents

Publication Publication Date Title
WO2008058145A3 (en) Therapeutic intra-vaginal devices & methods
WO2022010337A3 (es) Método para reducir la incidencia y prevalencia del virus del papiloma humano (vph) y para proporcionar protección contra infecciones de transmisión sexual
MX2020008778A (es) Metodo para reducir la incidencia y prevalencia del virus del papiloma humano (vph) y para proporcionar proteccion contra infecciones de transmision sexual.
CO5090882A1 (es) Nueva vacuna y procedimiento de uso des transmitidas sexualmente
Brown et al. Cavernous lymphangioma of the vulva
Nair et al. Granuloma genito-inguinale
Ramogola-Masire HPV vaccine for cervical cancer prevention in Botswana
Kunwar et al. Acquired gynatresia
Hakim et al. Indications and efficacy of the human papillomavirus vaccine
CN201899606U (zh) 一种真空耳塞
Rao et al. Two rare presentations of epidermal cyst
Cao et al. Randomized comparative trial in parous women of the frameless GyneFix® and the TCu380A intrauterine devices: long-term experience in a Chinese family planning clinic
CN206044832U (zh) 一种腮腺手术术后局部气压加压式包扎固定头套
CN2915146Y (zh) 医用阴道扩张器
Nyengidiki et al. Cervical cancer, a sequela of a sexually transmitted infection: the human papillomavirus infection
US20170231808A1 (en) Genital Shield for Reducing the Transmission of Sexually Transmitted Diseases
TWM452759U (zh) 舒適型迷你保險套
CN211797160U (zh) 一种全面防护的安全套
Sabuncuoglu et al. Moist secret mass; Buschke-Lowenste in tumor: a report of three cases
CN207412542U (zh) 双反折边密合框
Thomas et al. A rare case of TB cervix-cause of secondary amenorrhoea and primary infertility: case report
CN2870781Y (zh) 超保护安全套
CN205144500U (zh) 鼓气装置
CN200998348Y (zh) 加护型安全套
Sreenivasan PROTECTING AGAINST HPV-RELATED DISEASES: THE ROLE OF VACCINATION IN PREVENTING CERVICAL CANCER AND GENITAL WARTS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21838896

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202327007547

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021838896

Country of ref document: EP

Effective date: 20230206

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21838896

Country of ref document: EP

Kind code of ref document: A2